Patents Examined by Pierre P Eleniste
  • Patent number: 11970483
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or an optionally substituted C1-6 alkoxy group; and ring A is an optionally further substituted ring, or a salt thereof.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: April 30, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu Sasaki, Yasutomi Asano, Kazuaki Takami, Masaki Seto, Haruhi Ando
  • Patent number: 11970479
    Abstract: The present invention is directed to cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: April 30, 2024
    Assignees: Merck Sharp & Dohme LLC, MSD R&D (China) Co. LTD.
    Inventors: John J. Acton, III, Melissa Egbertson, Xiaolei Gao, Scott T. Harrison, Timothy J. Henderson, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Zhaoyang Meng, James Mulhearn, Vanessa L. Rada, Jeffrey W. Schubert, Oleg B. Selyutin, David M. Tellers, Ling Tong, Fengqi Zhang, Jianming Bao, Chunsing Li
  • Patent number: 11858902
    Abstract: The present disclosure relates to a novel compound suitable for a metal-free primary explosive, and the method of making and using the novel compound. The novel compound can undergo a deflagration to detonation transition (DDT) to initiate detonation of a larger body of secondary explosive.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: January 2, 2024
    Assignee: Purdue Research Foundation
    Inventors: Davin Glenn Piercey, Dominique Wozniak